Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03113344|
Recruitment Status : Recruiting
First Posted : April 13, 2017
Last Update Posted : December 19, 2017
|Condition or disease||Intervention/treatment|
|Children; Infection||Drug: cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|
1.Establish population pharmacokinetic (PPK) models of each anti-infective drug in children by nonlinear mixed effect modeling (NONMEM).
- At different timepoint after antibiotic administration, plasma samples of 100 children will be collected from neonatal intensive care unit (NICU) and pneumology department for each drug. The clinical information includes demography, medication, concentration data, blood biochemical parameters and so on .
- Plasma samples will be tested by high performance liquid chromatography (HPLC).
- PPK models of antibiotics will be established by NONMEM program.
- The reliability and stability of the PPK model will be evaluated by 1000 times of Bootstrap procedure and normalized predictive distribution error (NPDE).
2.Evaluation of the clinical feasibility and safety of individualized dosing.
- According the results of PPK models, we will use dosages recommended in models to cure children infectious diseases in prospective studies. For each antibiotic, 50 children will be collected.
- We will compare the therapeutic effects and safety between children with conventional therapies and children with individualized therapies, including proportions of children with effective drug concentration, improvement speed of of children, liver and kidney functions of of children, adverse reactions of drugs and so on.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||800 participants|
|Target Follow-Up Duration:||18 Years|
|Official Title:||Population Pharmacokinetics of Anti-infective Drugs in Children in Anti-infectious Therapies|
|Actual Study Start Date :||June 21, 2017|
|Estimated Primary Completion Date :||October 1, 2025|
|Estimated Study Completion Date :||December 31, 2025|
|Children with the usage of anti-infective drugs||
Drug: cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
- maximum concentration (Cmax) [ Time Frame: up to 4 weeks ]Cmax is a term used in pharmacokinetics refers to the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.
- time to achieve maximum concentration (Tmax) [ Time Frame: up to 4 weeks ]Tmax is the term used in pharmacokinetics to describe the time at which the Cmax is observed.
- absorption rate constant (ka) [ Time Frame: up to 4 weeks ]Ka is the rate constant of drug absorption.
- elimination rate constant (kel) [ Time Frame: up to 4 weeks ]The elimination rate constant is a value used in pharmacokinetics to describe the rate at which a drug is removed from the system.
- half-life (t1/2) [ Time Frame: up to 4 weeks ]Half-life is the time required for a quantity to reduce to half its initial value.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03113344
|Contact: A-Dong Shen, Masteremail@example.com|
|Beijing Children's Hospital of Capital Medical University||Recruiting|
|Contact: Adong Shen, Master 13370115087 firstname.lastname@example.org|
|Principal Investigator:||A-Dong Shen, Master||Beijing Children's Hospital of Capital Medical University|
|Study Director:||Yu-Jie Qi, Master||Beijing Children's Hospital of Capital Medical University|
|Study Director:||Wei Zhao, Doctor||Children's Hospital of Hebei Province;Shandong Provincial Qianfoshan Hospital|